Outcomes of Small Cell Lung Cancer Patients Treated With Cisplatin-Etoposide Versus Carboplatin-Etoposide
Authors:
- Shi Yuan JiangSJShi Yuan Jiang
- Mandip KhairaMKMandip Khaira
- Christopher W. LeeCLChristopher W. Lee
- Devin SchellenbergDSDevin Schellenberg
- 1 February 2015
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 38 (1) , 51-54
Abstract
This descriptive study compares overall survival (OS) and locoregional control (LRC) rates between cisplatin-etoposide (EP) and carboplatin-etoposide (EC) at a population level in patients with limited disease (LD) and extensive disease (ED) small cell lung cancer (SCLC). All patients diagnosed with SCLC from January 2004 to December 2008 were identified. Patients with LD SCLC treated with EP or EC and concurrent or sequential radiotherapy and those with ED SCLC treated with EP or EC were included for analysis. A retrospective review examining prognostic features and outcomes was performed. OS and LRC curves were calculated using the Kaplan-Meier method and compared with the log-rank test. A total of 249 patients with LD SCLC and 287 patients with ED SCLC were identified. Patients treated with EC were significantly older for both LD (median 62 vs. 72, P<0.001) and ED (median 62 vs. 73, P<0.001). Median follow-up times were 37 and 22 months for LD and ED SCLC, respectively. Median OS for EP and EC in LD SCLC patients were 23 and 18 months (P=0.10). LRC rates at 12 months were 81% for the EP group and 68% for the EC group (P=0.97). Median OS for the EP and EC patients with ED SCLC was 10 and 11 months, respectively, (P=0.24). Despite the preferential use of EC in an older population, median OS and LRC rates were not significantly different for patients treated with EP for both LD and ED SCLC.Keywords
This publication has 9 references indexed in Scilit:
- Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient DataJournal of Clinical Oncology, 2012
- Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702British Journal of Cancer, 2007
- A Review of First-Line Treatment for Small-cell Lung CancerJournal of Thoracic Oncology, 2006
- Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-UpJournal of Clinical Oncology, 2002
- Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and CarboplatinJournal of Clinical Oncology, 1999
- Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancerAnnals of Oncology, 1994
- Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.Journal of Clinical Oncology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982